Abstract
Objective: In the current economic context, it is critical to ensure that eating disorder (ED) treatments are both effective and cost-effective. We describe the impact of a novel clinical pathway developed to better meet the needs of autis- tic patients with EDs on the length and cost of hospital admissions.
Method: The pathway was based on the Institute for Healthcare's Model of Improvement methodology, using an iterative Plan, Do, Study, Act format to introduce change and to co-produce the work with people with lived experi- ence and with healthcare professionals. We explored the change in length and cost of admissions before and after the pathway was introduced.
Results: Preliminary results suggest that the treatment innovations associated with this pathway have led to reduced lengths of admission for patients with the comorbidity, which were not seen for patients without the comorbidity. Estimated cost-savings were approximately £22,837 per patient and approxi- mately £275,000 per year for the service as a whole.
Conclusion: Going forward, our aim is to continue to evaluate the effective- ness and cost-effectiveness of investment in the pathway to determine whether the pathway improves the quality of care for patients with a comorbid ED and autism and is good value for money.
Method: The pathway was based on the Institute for Healthcare's Model of Improvement methodology, using an iterative Plan, Do, Study, Act format to introduce change and to co-produce the work with people with lived experi- ence and with healthcare professionals. We explored the change in length and cost of admissions before and after the pathway was introduced.
Results: Preliminary results suggest that the treatment innovations associated with this pathway have led to reduced lengths of admission for patients with the comorbidity, which were not seen for patients without the comorbidity. Estimated cost-savings were approximately £22,837 per patient and approxi- mately £275,000 per year for the service as a whole.
Conclusion: Going forward, our aim is to continue to evaluate the effective- ness and cost-effectiveness of investment in the pathway to determine whether the pathway improves the quality of care for patients with a comorbid ED and autism and is good value for money.
| Original language | English |
|---|---|
| Pages (from-to) | 1-5 |
| Number of pages | 1 |
| Journal | European Eating Disorders Review |
| DOIs | |
| Publication status | Published - 10 Jul 2020 |
Keywords
- Autism Spectrum Disorder
- Eating Disorders
- Health economics
- treatment
- autism spectrum disorders
- eating disorders
- health economics
